Diamedica Therapeutics (DMAC) Price & Analysis

Compare

505 Followers

DMAC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.19 - $6.82

Previous CloseN/A

Volume70.76K

Average Volume (3M)424.01K

Market Cap

$180.97M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Aug 06, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding42,883,465

10 Day Avg. Volume579,627

30 Day Avg. Volume424,011

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$11.33

Price Target Upside175.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

KOL SupportThe company's hosted KOL event on pregnancy complication preeclampsia showed specialist enthusiasm for a viable preeclampsia treatment, which currently lacks FDA-approved therapy.

Safety ProfileNo demonstrated placental transfer across all cohorts, which is considered paramount to the safety profile of DM199.

Therapeutic PotentialPositive interim results from Part 1a of the Phase 2 study show therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints.

Bears Say

Market PotentialEarly proof-of-concept signals in preeclampsia could be supportive of DM199 and reiterate a Buy rating.

Trial De-riskingThe interim Phase 2 update provided de-risking for the PE program based on consistent demonstrated benefits, supporting trial continuation.

Diamedica Therapeutics News

DiaMedica Therapeutics files to sell 8.61M common shares for holders

08:32 EDT DiaMedica Therapeutics (DMAC) files to sell 8.61M common shares for holders Published first on TheFly –...

1d ago

DMAC

DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement

DiaMedica Therapeutics (DMAC) announced definitive agreements for a $30.1M private placement of common shares led by current investors....

12d ago

DMAC

DiaMedica Therapeutics price target raised to $11 from $8 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $11 from $8 and...

15d ago

DMAC

DiaMedica Therapeutics price target raised to $14 from $11 at Lake Street

Lake Street raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $14 from $11 and keeps a...

15d ago

DMAC

DiaMedica Therapeutics price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $12 from $10 and keeps a...

15d ago

DMAC

DiaMedica Therapeutics reports interim results from DM199 study

DiaMedica Therapeutics (DMAC) Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced interim results from Part 1a of...

16d ago

DMAC

ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment?

Diamedica Therapeutics (($DMAC)) announced an update on their ongoing clinical study. The ReMEDy2 Trial, officially titled ‘Phase 2/3...

3d ago

DMAC

DiaMedica Therapeutics Secures $30.1 Million in Private Placement

Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. DiaMedica Therapeutics has successfully closed a $30.1 million private...

10d ago

DMAC

DiaMedica Announces $30.1M Private Placement for DM199

Diamedica Therapeutics ( ($DMAC) ) has shared an announcement. On July 21, 2025, DiaMedica Therapeutics announced a $30.1...

12d ago

DMAC

DiaMedica Announces Positive Interim Results for DM199 Study

An update from Diamedica Therapeutics ( ($DMAC) ) is now available. On July 17, 2025, DiaMedica Therapeutics announced...

16d ago

DMAC

ReMEDy2 Trial: A New Hope for Acute Ischemic Stroke Treatment

Diamedica Therapeutics (($DMAC)) announced an update on their ongoing clinical study. Study Overview: The ReMEDy2 Trial, officially titled...

23d ago

DMAC

DiaMedica Therapeutics to be included in Russell 2000, 3000 Indexes

DiaMedica Therapeutics (DMAC) announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell...

1M ago

DMAC

Promising Potential of Diamedica Therapeutics’ DM199 in Preeclampsia Treatment Drives Buy Rating

Diamedica Therapeutics (DMAC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

DMAC

DiaMedica Therapeutics’ Earnings Call Highlights Progress and Stability

Diamedica Therapeutics (($DMAC)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

DMAC

DMAC FAQ

What was Diamedica Therapeutics Inc’s price range in the past 12 months?

Diamedica Therapeutics Inc lowest stock price was $3.19 and its highest was $6.82 in the past 12 months.

What is Diamedica Therapeutics Inc’s market cap?

Diamedica Therapeutics Inc’s market cap is $180.97M.

When is Diamedica Therapeutics Inc’s upcoming earnings report date?

Diamedica Therapeutics Inc’s upcoming earnings report date is Aug 06, 2025 which is in 4 days.

How were Diamedica Therapeutics Inc’s earnings last quarter?

Diamedica Therapeutics Inc released its earnings results on May 13, 2025. The company reported -$0.18 earnings per share for the quarter, the consensus estimate of -$0.18 by $0.

Is Diamedica Therapeutics Inc overvalued?

According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Diamedica Therapeutics Inc pay dividends?

Diamedica Therapeutics Inc does not currently pay dividends.

What is Diamedica Therapeutics Inc’s EPS estimate?

Diamedica Therapeutics Inc’s EPS estimate is -0.19.

How many shares outstanding does Diamedica Therapeutics Inc have?

Diamedica Therapeutics Inc has 42,883,465 shares outstanding.

What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?

Diamedica Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, expectations of -$0.18. Following the earnings report the stock price went up 0.503%.

Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?

Currently, no hedge funds are holding shares in DMAC

Diamedica Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-67.25%

Trailing 12-Months

Asset Growth

-21.17%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Diamedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Diamedica Therapeutics (DMAC) Earnings & Revenues

DMAC Earnings Data >

DMAC Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook with significant progress in clinical programs and financial stability, despite some increased operational expenses.Read More>

DMAC Stock 12 Month Forecast

Average Price Target

$11.33

▲(175.00%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.218461538461538,4.866923076923077,5.515384615384615,6.163846153846153,6.812307692307693,7.46076923076923,8.109230769230768,8.757692307692308,9.406153846153845,10.054615384615385,10.703076923076923,11.35153846153846,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.1669230769230765,4.763846153846154,5.360769230769231,5.957692307692307,6.554615384615385,7.151538461538461,7.748461538461537,8.345384615384615,8.942307692307692,9.53923076923077,10.136153846153846,10.733076923076922,{"y":11.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.57,4.141538461538461,4.7130769230769225,5.2846153846153845,5.8561538461538465,6.427692307692308,6.999230769230769,7.570769230769232,8.142307692307693,8.713846153846154,9.285384615384615,9.856923076923078,10.428461538461539,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.73,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.34,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >